SCPHARMACEUTICALS INC (SCPH) Stock Price & Overview
NASDAQ:SCPH • US8106481059
Current stock price
The current stock price of SCPH is 5.67 USD. Today SCPH is down by 0%. In the past month the price increased by 1.7%. In the past year, price increased by 34.04%.
SCPH Key Statistics
- Market Cap
- 304.366M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.81
- Dividend Yield
- N/A
SCPH Stock Performance
SCPH Stock Chart
SCPH Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to SCPH. When comparing the yearly performance of all stocks, SCPH is one of the better performing stocks in the market, outperforming 88.16% of all stocks.
SCPH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SCPH. SCPH may be in some trouble as it scores bad on both profitability and health.
SCPH Earnings
On August 7, 2025 SCPH reported an EPS of -0.34 and a revenue of 16.04M. The company missed EPS expectations (-11.86% surprise) and beat revenue expectations (2.03% surprise).
SCPH Forecast & Estimates
10 analysts have analysed SCPH and the average price target is 12.33 USD. This implies a price increase of 117.45% is expected in the next year compared to the current price of 5.67.
For the next year, analysts expect an EPS growth of 41.66% and a revenue growth 100.79% for SCPH
SCPH Groups
Sector & Classification
SCPH Financial Highlights
Over the last trailing twelve months SCPH reported a non-GAAP Earnings per Share(EPS) of -1.81. The EPS decreased by -16.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -114.28% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SCPH Ownership
SCPH Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.94 | 855.344B | ||
| JNJ | JOHNSON & JOHNSON | 20.21 | 566.915B | ||
| MRK | MERCK & CO. INC. | 22.06 | 282.297B | ||
| PFE | PFIZER INC | 9.03 | 153.415B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.08 | 117.056B | ||
| ZTS | ZOETIS INC | 16.34 | 48.828B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.78 | 26.166B | ||
| VTRS | VIATRIS INC | 5.26 | 15.198B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.8 | 11.922B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.026B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.799B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.144B | ||
| LGND | LIGAND PHARMACEUTICALS | 24.12 | 4.084B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SCPH
Company Profile
scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. The company is headquartered in Burlington, Massachusetts and currently employs 162 full-time employees. The company went IPO on 2017-11-17. The firm is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company’s strategy is to develop therapies for subcutaneous administration that have previously been limited to intravenous (IV) delivery. Its commercial product, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Company’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Company Info
IPO: 2017-11-17
SCPHARMACEUTICALS INC
25 Mall Road, Suite 203
Burlington MASSACHUSETTS 01803 US
CEO: John H. Tucker
Employees: 163
Phone: 16175170730
SCPHARMACEUTICALS INC / SCPH FAQ
What does SCPHARMACEUTICALS INC do?
scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. The company is headquartered in Burlington, Massachusetts and currently employs 162 full-time employees. The company went IPO on 2017-11-17. The firm is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company’s strategy is to develop therapies for subcutaneous administration that have previously been limited to intravenous (IV) delivery. Its commercial product, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Company’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
What is the stock price of SCPHARMACEUTICALS INC today?
The current stock price of SCPH is 5.67 USD.
What is the dividend status of SCPHARMACEUTICALS INC?
SCPH does not pay a dividend.
How is the ChartMill rating for SCPHARMACEUTICALS INC?
SCPH has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists SCPH stock?
SCPH stock is listed on the Nasdaq exchange.
Can you provide the upcoming earnings date for SCPHARMACEUTICALS INC?
SCPHARMACEUTICALS INC (SCPH) will report earnings on 2025-11-05, after the market close.